-
Tytuł:
-
Evaluation of Poly(I:C) and combination of CpG ODN plus Montanide ISA adjuvants to enhance the efficacy of outer membrane vesicles as an acellular vaccine against Brucella melitensis infection in mice.
-
Autorzy:
-
Golshani M; Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran.
Amani M; Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran.
Amirzadeh F; Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran.
Nazeri E; Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran.
Davar Siadat S; Tuberculosis and Pulmonary Research Department, Pasteur Institute of Iran, Tehran, Iran.
Nejati-Moheimani M; Bacterial Vaccine and Antigen Production Branch, Pasteur Institute of Iran, Karaj, Iran.
Arsang A; Bacterial Vaccine and Antigen Production Branch, Pasteur Institute of Iran, Karaj, Iran.
Bouzari S; Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran. Electronic address: .
-
Źródło:
-
International immunopharmacology [Int Immunopharmacol] 2020 Jul; Vol. 84, pp. 106573. Date of Electronic Publication: 2020 May 23.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Amsterdam ; New York : Elsevier Science, c2001-
-
MeSH Terms:
-
Adjuvants, Immunologic/*administration & dosage
Bacterial Outer Membrane/*immunology
Brucella Vaccine/*administration & dosage
Brucellosis/*prevention & control
Cell Membrane Structures/*immunology
Mannitol/*analogs & derivatives
Oleic Acids/*administration & dosage
Oligodeoxyribonucleotides/*administration & dosage
Poly I-C/*administration & dosage
Animals ; Brucella melitensis/drug effects ; Brucella melitensis/growth & development ; Cytokines/immunology ; Female ; Immunoglobulin G/immunology ; Mannitol/administration & dosage ; Mice, Inbred BALB C
-
Contributed Indexing:
-
Keywords: Adjuvant; Burucella melitensis; CpG; Montanide ISA; OMVs; Poly(I:C); Vaccine
-
Substance Nomenclature:
-
0 (Adjuvants, Immunologic)
0 (Brucella Vaccine)
0 (CpG ODN 1826)
0 (Cytokines)
0 (Immunoglobulin G)
0 (Oleic Acids)
0 (Oligodeoxyribonucleotides)
0 (montanide ISA 51)
3OWL53L36A (Mannitol)
O84C90HH2L (Poly I-C)
-
Entry Date(s):
-
Date Created: 20200527 Date Completed: 20210311 Latest Revision: 20210311
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.intimp.2020.106573
-
PMID:
-
32454410
-
Brucellosis is the most common zoonotic disease worldwide and still there is no vaccine for human use. The commercial animal vaccines also have major problems that limit their use. Therefore, there is a need for an effective Brucella vaccine which is multivalent and produces a good protective immunity with minimal disadvantages. Due to their heterogeneous composition and diverse functions, OMVs are promising acellular vaccine candidates against brucellosis. In the present study, the potential of Poly(I:C) or CpG ODN 1826+ Montanide ISA 70 VG adjuvant formulations were evaluated to enhance the immunity and protection levels conferred by OMVs against Brucella challenge in mice. The results indicated that both vaccine regimens were able to induce strong Th1-biased responses and confer protective levels significantly higher than REV.1 live vaccine. With regard to the results, it is concluded that OMVs in either adjuvant can be introduced as a new vaccine candidate against B. melitensis infection.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2020 Elsevier B.V. All rights reserved.)
